- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bisprolol safer than carvedilol in Hemodialysis patients for lowering HF, stroke risk: Study
Persons with end-stage kidney disease (ESKD) undergoing dialysis are at high risk of developing and dying from cardiovascular (CV) disease, for which they often receive β-blockers (BBs) despite scarce interventional evidence on their benefit in them.
A recent study suggests that compared with carvedilol, bisoprolol initiation by Hemodialysis (HD) patients was associated with a lower 2-year risk of death and MACEs, mainly attributed to lower heart failure and ischemic stroke risk. The research findings were published in the Clinical Kidney Journal on January 4, 2021.
The BB class is heterogeneous concerning pharmacodynamics and pharmacokinetics. Ping-Hsun Wu, MD, of Kaohsiung Medical University Hospital, and colleagues wrote, "In many health systems, bisoprolol and carvedilol are the two most commonly used BBs. Bisoprolol may offer advantages over carvedilol because of its β1 selectivity and moderate dialyzability with less intradialytic hypotension potential. The objective of this study was to evaluate the risk for all-cause mortality and CV events associated with bisoprolol compared with carvedilol in HD patients".
Researchers conducted a cohort study of 9305 HD patients who initiated bisoprolol and 11 171 HD patients who initiated carvedilol treatment between 2004 and 2011. They assigned the subjects in one of the following groups:
• High-dose bisoprolol (≥10 mg/day),
• Low-dose bisoprolol (≥1.25–<10 mg/day),
• High-dose carvedilol (≥50 mg/day) and
• Low-dose carvedilol (≥6.25–<50 mg/day).
The major outcome assessed was the risk of all-cause mortality and major adverse cardiovascular events (MACEs) between carvedilol and bisoprolol users during a 2-year follow-up.
Key findings of the study:
♦ They found that bisoprolol initiators were younger, had shorter dialysis vintage, were women, had common comorbidities of hypertension and hyperlipidemia and were receiving statins and antiplatelets, but they had less heart failure and digoxin prescriptions than carvedilol initiators.
♦ They recorded 1555 deaths and 5167 MACEs events.
♦ Upon the multivariable-adjusted Cox model, they found that bisoprolol initiation was associated with lower all-cause mortality (hazard ratio [HR] 0.66) compared with carvedilol initiation.
♦ They also found that bisprolol initiation is associated with the low risk of MACEs (HR = 0.85), heart failure (HR = 0.83) and ischemic stroke (HR = 0.84). However, they noted no differences in the risk of acute myocardial infarction (HR 1.03).
The authors concluded, "Our study showed that relative to carvedilol, bisoprolol initiation in patients undergoing HD was associated with a lower risk of death and MACEs. While our findings may inform clinical decisions regarding the choice of BBs in this high-risk population. In the absence of trial evidence, this study may inform the choice of BB therapy in this high-CV-risk population with a void of evidence".
For further information:
DOI: https://doi.org/10.1093/ckj/sfaa248
Dr Kartikeya Kohli is an Internal Medicine Consultant at Sitaram Bhartia Hospital in Delhi with super speciality training in Nephrology. He has worked with various eminent hospitals like Indraprastha Apollo Hospital, Sir Gangaram Hospital. He holds an MBBS from Kasturba Medical College Manipal, DNB Internal Medicine, Post Graduate Diploma in Clinical Research and Business Development, Fellow DNB Nephrology, MRCP and ECFMG Certification. He has been closely associated with India Medical Association South Delhi Branch and Delhi Medical Association and has been organising continuing medical education programs on their behalf from time to time. Further he has been contributing medical articles for their newsletters as well. He is also associated with electronic media and TV for conduction and presentation of health programs. He has been associated with Medical Dialogues for last 3 years and contributing articles on regular basis.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751